Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

NCT01945294 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

257

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Boceprevir
BIOLOGICAL: Peg-interferon alfa-2b
DRUG: Ribavirin

Sponsor

Merck Sharp & Dohme LLC